Covid-19 vaccine from Novavax

15. July 2022 – The company holding the marketing authorisation for the Nuvaxovid vaccine applied for an indication extension for the vaccine to adolescents aged 12 to 18 years. It also applied for authorisation of a new dosage recommendation for a booster dose for persons aged 18 years and over. The Covid-19 vaccine Nuvaxovid has been licensed for basic immunisation in Switzerland since 12 April 2022 for persons aged 18 years and older. Swissmedic examines the application documents received in an accelerated manner, but without compromising the scientific examination.

For more information, see here.